592542-82-0

Basic information

• Product Name: Alanine, N-[2-Methoxy-5-[[[(1E)-2-(2,4,6-triMethoxyphenyl)ethenyl]sulfonyl]Methyl]phenyl]-
• Synonyms: Alanine, N-[2-Methoxy-5-[[[(1E)-2-(2,4,6-triMethoxyphenyl)ethenyl]sulfonyl]Methyl]phenyl]-
• CAS NO: 592542-82-0
• Molecular Formula: C₂₂H₂₇NO₈S
• Molecular Weight: 465.51668
• Mol File: 592542-82-0.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Alanine, N-[2-Methoxy-5-[[[(1E)-2-(2,4,6-triMethoxyphenyl)ethenyl]sulfonyl]Methyl]phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Alanine, N-[2-Methoxy-5-[[[(1E)-2-(2,4,6-triMethoxyphenyl)ethenyl]sulfonyl]Methyl]phenyl]-(592542-82-0)
• EPA Substance Registry System: Alanine, N-[2-Methoxy-5-[[[(1E)-2-(2,4,6-triMethoxyphenyl)ethenyl]sulfonyl]Methyl]phenyl]-(592542-82-0)

Safety Data

• Hazardous Substances Data: 592542-82-0(Hazardous Substances Data)

Upstream product

• 31680-08-7 4-methoxy-3-nitrobenzaldehyde 
• 136612-71-0 (2,4,6-Trimethoxyphenyl)acetylene 
• 830-79-5 2,4,6-trimethoxybenzaldehyde 
• 41870-24-0 (4-methoxy-3-nitrophenyl)methanol 
• 119-10-8 4-methoxy-3-nitrotoluene 
• 1330633-87-8 2-(2’,2’-dibromovinyl)-1,3,5-trimethoxybenzene 
• 1330633-86-7 (E)-2',4',6'-trimethoxystyryl-4-methoxy-3-nitrobenzyl sulfide 
• 908344-21-8 3-nitro-4-methoxybenzyl mercaptan 
• 908344-08-1 (E)-2',4',6'-trimethoxystyryl-4-methoxy-3-aminobenzyl sulfide 
• 592542-50-2 (E)-2-methoxy-5-(((2,4,6-trimethoxystyryl)sulfonyl)methyl)aniline 
• 592542-51-3 4-methoxy-3-nitrophenylmethanesulfonyl acetic acid 
• 22216-44-0 2-(4-methoxy-3-nitrobenzylthio)acetic acid 
• 911294-96-7 (E)-methyl 2-(2-methoxy-5-((2',4',6'-trimethoxystyrylsulfonyl)methyl)phenylamino)propanoate 

Relevant articles and documents

Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl] phenylamino}acetate (ON 01910.Na): Synthesis, structure-activity relationship, and biological activity

Cyclin D proteins are elevated in many cancer cells, and targeted deletion of cyclin D1 gene in the mammary tissues protects mice from breast cancer. Accordingly, there is an increasing awareness of this novel nonenzymatic target for cancer therapeutics. We have developed novel, nonalkylating styrylbenzylsulfones that induce cell death in wide variety of cancer cells without affecting the proliferation and survival of normal cells. The development of derivatized styrylbenzylsulfones followed logically from a tumor cell cytotoxicity screen performed in our laboratory that did not have an a priori target profile. Modifications of some of the precursor molecules led to lead optimization with regard to tumor cell cytotoxicity. In this report we describe the synthesis and structure-activity relationships of novel, nonalkylating (E)-styrylbenzylsulfones and the development of the novel anticancer agent sodium (E)-2-{2-methoxy-5-[(2′,4′,6′- trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na), which is in phase III trials for myelodysplastic syndromes (MDS) associated with aberrant expression of cyclin D proteins.

COMPOSITION AND METHODS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA

Methods and compositions are provided for treating myelodysplastic syndrome and acute myeloid leukemia, wherein the composition comprises at least one compound according to Formula I: (I) wherein R1 is selected from the group consisting of -NH2, -NH-CH2-CO2H, -NH-CH(CH3)-CO2H, and -NH-C(CH3)2-CO2H, or a pharmaceutically acceptable salt of such a compound; and a DNA methyltransferase inhibitor, or a pharmaceutically acceptable salt thereof.